EQ - NASDAQ

Equillium, Inc.

EQ·NASDAQ

$3.15

-1.6%

HealthcareBiotechnology

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$111.89M

EPS-0.3900

P/E Ratio-8.08

Earnings Date08/12/2026

31.89M

Assets

25%

3Y-59.0%

5Y-63.0%

10Y+346.0%

3.29M

Total Liabilities

-50%

3Y-93.0%

5Y-79.0%

10Y-65.0%

28.60M

Total Equity

50%

3Y-10.0%

5Y-59.0%

10Y-1370.0%

Equillium, Inc. Funding & Solvency Profile

EQ · NASDAQ

Current Assets

Cash & Cash Equivalents30.28M

Net Receivables108.00K

Inventory0.00

Other Current Assets-547.00K

Total Current Assets30 M

Non-Current Assets

Property, Plant & Equipment658.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets658 K

Total Assets

31.89M

Financial Health Analysis

Current Ratio

10.32x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.12x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

27 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Equillium, Inc. Balance Sheet

EQ • NASDAQ

Equillium, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	30.3M	18.1M	23.2M	59.1M	50.4M	24M	13.2M	28.5M	7.1M
Short-Term Investments	0.0	4.5M	17.7M	11.9M	30.3M	58.2M	39.9M	37.4M	0.0
Cash & Short-Term Investments	30.3M	22.6M	40.9M	71M	80.7M	82.2M	53.1M	65.9M	7.1M
Net Receivables	108K	1.1M	6.3M	4.1M	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	0.0	3.7M	2.8M	0.0	0.0	0.0	0.0	0.0
Other Receivables	108K	1.1M	2.6M	1.3M	0.0	0.0	0.0	0.0	0.0
Prepaids	439K	830K	2M	1.6M	2.7M	3M	2.3M	1.2M	45.8K
Other Current Assets	-547K	429K	235K	8K	0.0	0.0	0.0	0.0	0.0
Total Current Assets	30.3M	25M	49.3M	76.7M	83.4M	85.2M	55.5M	67.2M	7.1M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	658K	626K	1.1M	1.6M	1.9M	239K	93K	63.5K	2.1K
Other Non-Current Assets	0.0	0.0	70K	104K	153K	15K	-93K	0.0	0.0
Total Non-Current Assets	658K	626K	1.2M	1.7M	2M	254K	108K	63.5K	2.1K
Other Assets	952K	0.0	0.0	0.0	0.0	0.0	-108K	-63.5K	0.0
Total Assets	31.9M	25.6M	50.5M	78.4M	85.4M	85.4M	55.5M	67.2M	7.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	755K	3M	4.7M	4M	1.2M	2.8M	1.9M	1.1M	428.3K
Accounts Payable	755K	2.7M	4.7M	4M	1.2M	2.8M	1.9M	1.1M	243.7K
Other Payables	0.0	365K	0.0	0.0	0.0	0.0	0.0	0.0	-243.7K
Accrued Expenses	0.0	437K	3.1M	7.2M	2.5M	2.8M	1.2M	559.5K	140.6K
Short Term Debt	363K	197K	0.0	5.7M	1.4M	1.7M	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	440K	408K	376K	0.0	0.0	0.0	0.0
Tax Payables	0.0	365K	0.0	0.0	0.0	0.0	0.0	0.0	184.5K
Deferred Revenue	0.0	0.0	15.7M	14.7M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	1.8M	2.7M	3.6M	0.0	3.4M	0.0	795K	349.5K	0.0
Total Current Liabilities	2.9M	6.4M	27.6M	32M	8.9M	7.2M	3.9M	2M	568.8K
NON-CURRENT LIABILITIES
Long Term Debt	356K	0.0	0.0	3.2M	8.8M	8.3M	9.7M	0.0	8.1M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	10.4M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	54K	127K	0.0	775.8K
Total Non-Current Liabilities	356K	187K	384K	14.4M	10M	8.3M	9.8M	200K	8.8M
Capital Lease Obligations	0.0	187K	824K	1.2M	1.6M	0.0	0.0	0.0	0.0
Total Liabilities	3.3M	6.5M	28M	46.5M	18.9M	15.6M	13.7M	2.2M	9.4M
SHAREHOLDERS' EQUITY
Common Stock	5K	3K	3K	3K	2K	2K	1K	789.0	124.0
Additional Paid-In Capital	244.4M	212.1M	208.2M	204.3M	176.6M	141.1M	82.9M	80.4M	9.7K
Retained Earnings	-216.2M	-193.8M	-185.7M	-172.4M	-110M	-70.9M	-41.1M	-15.5M	-2.3M
Accumulated Other Comprehensive Income/Loss	363K	781K	140K	76K	-138K	-297K	21K	5.3K	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6K	0.0
Total Stockholders' Equity	28.6M	19.1M	22.6M	31.9M	66.5M	69.9M	41.8M	64.9M	-2.3M
Total Equity	28.6M	19.1M	22.6M	31.9M	66.5M	69.9M	41.8M	64.9M	-2.3M
SUMMARY
Total Liabilities & Equity	31.9M	25.6M	50.5M	78.4M	85.4M	85.4M	55.5M	67.2M	7.2M
Total Investments	0.0	4.5M	17.7M	11.9M	30.3M	58.2M	39.9M	37.4M	0.0
Total Debt	719K	384K	824K	10.2M	11.8M	9.9M	9.7M	200K	8.1M
Net Debt	-29.6M	-17.7M	-22.4M	-48.9M	-38.6M	-14M	-3.5M	-28.3M	955.3K
Shares Outstanding	35,521,459	35,521,459	35,521,459	35,521,459	35,521,459	35,521,459	35,521,459	35,521,459	35,521,459

SEC Filings

EQ - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 28, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 15, 2026	May 28, 2026	2026	View Filing
S-3 S-3 N/A	April 07, 2026	April 07, 2026		View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 13, 2026	March 11, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
S-3 S-3 N/A	November 13, 2025	November 13, 2025		View Filing

Showing 1 to 10 of 158 filings

Related Guides

Blog Categories

Continue your EQ research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.